drugset

drugset / Trial / NCT01907113

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BI 10773 in Type II Diabetes Patients With Different Degrees of Renal Impairment

NCT01907113 ↗

Phase 1 Completed 40 enrolled Boehringer Ingelheim

Non-randomizedParallel-groupOpen-labelTreatment

Summary

Assessment of the effect of normal and impaired kidney function on the pharmacokinetics, pharmacodynamics and safety of BI 10773

Timeline

Start: 2009-07
Primary completion: 2009-12
Completion: 2009-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Empagliflozin	Small molecule	50 mg	Oral

Indications